1. Clinical & Scientific Overview
Rituximab (TIP-MED-000575, Reference Code [ONC-26]) is classified under
Oncology & Antineoplastic Medicines as a Monoclonal Antibody (Anti-CD20 Biologic) • Chimeric Murine/Human Anti-CD20 Monoclonal Antibody.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Specialist Oncology Supervision).
MabThera / Ristova (Roche Products India), Reditux (Dr. Reddy's Laboratories), Truxima / Blitzima (Celltrion / Biocon)
Concentrate for IV Infusion: 100 mg/10 mL, 500 mg/50 mL vials
Oncology Specialisation & Cytotoxic Safety Protocol
Monoclonal Antibody (Anti-CD20 Biologic)
Antineoplastic Biologic
Standard Regimen & Cycle Context: Oncology (NHL): 375 mg/m2 IV infusion on Day 1 of each chemotherapy cycle.
Signature Dose-Limiting Toxicities & Organ Monitoring: BOXED WARNINGS: (1) Severe First-Infusion Cytokine-Release / Hypersensitivity Reactions (bronchospasm, hypotension, rigors within 30–120 min of first infusion); (2) Hepatitis B Virus (HBV) Reactivation causing fulminant hepatic failure; (3) Progressive Multifocal Leukoencephalopathy (PML — JC virus reactivation); and (4) Tumour Lysis Syndrome in high-burden lymphoma.
Extravasation, Premedication & Safe Cytotoxic Handling: MANDATORY SCREENING & PREMEDICATION: Screen ALL patients for HBsAg AND anti-HBc total before starting (if positive, start prophylactic entecavir/tenofovir); premedicate 30 min prior with Paracetamol + H1 Antihistamine + Corticosteroid; start first infusion slowly at 50 mg/hr and escalate by 50 mg/hr every 30 min (max 400 mg/hr) if tolerated.
3. Mechanism of Action & Pharmacodynamics
Binds the transmembrane phosphoprotein CD20 on pre-B and mature B-lymphocytes, inducing B-cell lysis via Antibody-Dependent Cellular Cytotoxicity (ADCC), Complement-Dependent Cytotoxicity (CDC), and direct apoptosis.
4. Therapeutic Indications & Evidence-Supported Uses
- CD20-positive B-cell Non-Hodgkin Lymphoma (DLBCL, Follicular Lymphoma — R-CHOP / R-Bendamustine)
- Chronic Lymphocytic Leukaemia (CLL)
- Severe Rheumatoid Arthritis, ANCA-Associated Vasculitis, and Pemphigus Vulgaris
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Oncology Regimen Context (Specialist Reference Only): Oncology (NHL): 375 mg/m2 IV infusion on Day 1 of each chemotherapy cycle.
Administration & Meal Timing: Oncology (NHL): 375 mg/m2 IV infusion on Day 1 of each chemotherapy cycle.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Specialist oncology pharmacokinetic profile; dosing depends on Body Surface Area (BSA in m2), Calvert GFR formula, or flat targeted dosing with strict organ-function adjustments.
Hepatic enzymatic activation/inactivation or proteolytic degradation (for monoclonal antibodies); see specific polymorphism and interaction notes.
Verify serum creatinine and eGFR before every cycle; see drug-specific renal dosing and uroprotection rules.
Check total bilirubin, AST, and ALT prior to each cycle; taxanes, anthracyclines, and TKIs require strict hepatic dose modification.
7. Contraindications, Precautions & High-Risk Warnings
- Severe hypersensitivity to Rituximab or formulation vehicle
- Pregnancy and lactation (potent teratogen/embryotoxic class warning unless explicitly evaluated by oncology specialist)
- Severe unrecovered bone marrow aplasia or decompensated organ failure per protocol thresholds
Key Clinical Precautions: BOXED WARNINGS: (1) Severe First-Infusion Cytokine-Release / Hypersensitivity Reactions (bronchospasm, hypotension, rigors within 30–120 min of first infusion); (2) Hepatitis B Virus (HBV) Reactivation causing fulminant hepatic failure; (3) Progressive Multifocal Leukoencephalopathy (PML — JC virus reactivation); and (4) Tumour Lysis Syndrome in high-burden lymphoma.
8. Adverse Effects Profile
- BOXED WARNINGS: (1) Severe First-Infusion Cytokine-Release / Hypersensitivity Reactions (bronchospasm, hypotension, rigors within 30–120 min of first infusion); (2) Hepatitis B Virus (HBV) Reactivation causing fulminant hepatic failure; (3) Progressive Multifocal Leukoencephalopathy (PML — JC virus reactivation); and (4) Tumour Lysis Syndrome in high-burden lymphoma.
- BOXED WARNINGS: (1) Severe First-Infusion Cytokine-Release / Hypersensitivity Reactions (bronchospasm, hypotension, rigors within 30–120 min of first infusion); (2) Hepatitis B Virus (HBV) Reactivation causing fulminant hepatic failure; (3) Progressive Multifocal Leukoencephalopathy (PML — JC virus reactivation); and (4) Tumour Lysis Syndrome in high-burden lymphoma.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- BOXED WARNINGS: (1) Severe First-Infusion Cytokine-Release / Hypersensitivity Reactions (bronchospasm, hypotension, rigors within 30–120 min of first infusion); (2) Hepatitis B Virus (HBV) Reactivation causing fulminant hepatic failure; (3) Progressive Multifocal Leukoencephalopathy (PML — JC virus reactivation); and (4) Tumour Lysis Syndrome in high-burden lymphoma.
- Avoid live-attenuated vaccines during immunosuppressive chemotherapy; verify CYP3A4, UGT1A1, DPD, and QTc interactions before each cycle.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: MANDATORY SCREENING & PREMEDICATION: Screen ALL patients for HBsAg AND anti-HBc total before starting (if positive, start prophylactic entecavir/tenofovir); premedicate 30 min prior with Paracetamol + H1 Antihistamine + Corticosteroid; start first infusion slowly at 50 mg/hr and escalate by 50 mg/hr every 30 min (max 400 mg/hr) if tolerated.
Pharmacist Patient Counselling Points:
- MANDATORY SCREENING & PREMEDICATION: Screen ALL patients for HBsAg AND anti-HBc total before starting (if positive, start prophylactic entecavir/tenofovir); premedicate 30 min prior with Paracetamol + H1 Antihistamine + Corticosteroid; start first infusion slowly at 50 mg/hr and escalate by 50 mg/hr every 30 min (max 400 mg/hr) if tolerated.
- Report fever >=38.0°C (100.4°F) immediately (medical emergency: possible febrile neutropenia).
- Follow strict reproductive contraception and safe cytotoxic oral handling instructions.
Storage, Stability & Dispensing Safeguards: MANDATORY SCREENING & PREMEDICATION: Screen ALL patients for HBsAg AND anti-HBc total before starting (if positive, start prophylactic entecavir/tenofovir); premedicate 30 min prior with Paracetamol + H1 Antihistamine + Corticosteroid; start first infusion slowly at 50 mg/hr and escalate by 50 mg/hr every 30 min (max 400 mg/hr) if tolerated.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: National Cancer Grid (NCG) India Consensus Guidelines; NLEM 2022 Antineoplastic Section; Indian Pharmacopoeia (IP) & CDSCO Approved Oncology Prescribing Information.
Official Verification Portals: National Cancer Grid (NCG) India — Evidence-Based Oncology Guidelines • CDSCO — Central Drugs Standard Control Organization Approved Drug Data • Indian Pharmacopoeia Commission (IPC)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [ONC-25] Bortezomib — Targeted Therapy (Proteasome Inhibitor) • Reversible Dipeptidyl B
- [ONC-27] Trastuzumab — Monoclonal Antibody (Anti-HER2 Targeted Biologic) • Humanised Ant
- [ONC-28] Pembrolizumab — Immune Checkpoint Inhibitor (Immuno-Oncology) • Humanised Anti-PD
- [ONC-29] Filgrastim (rHuG-CSF) — Oncology Supportive Care (Myeloid Growth Factor) • Recombinant Me
